Latest Regulatory Approvals News

Tartana Minerals partners with Alt Resources in a $2 million joint venture to accelerate exploration of critical metals in Far North Queensland, focusing on tin, tungsten, and rare earth elements.

Elsight’s Halo platform has advanced to the final phase of a major U.S. Defense Innovation Unit challenge, securing significant funding and positioning the company at the forefront of a generational unmanned systems investment cycle.

Mayne Pharma updates investors on the extended FIRB approval deadline and potential financing hurdles in its proposed acquisition by Cosette Pharmaceuticals.

Emerald Resources has secured full development and operational permits for its Memot Gold Project in Cambodia, alongside an extension of the Okvau Gold Mine agreement to support underground mining. These approvals mark a pivotal step in the company’s expansion plans in Southeast Asia.

Excelsior Capital has settled its Federal Court dispute with London City Equities, paving the way for a capital return, fully franked dividend, and eventual delisting from the ASX.

Infomedia Ltd shareholders have overwhelmingly approved a scheme of arrangement for acquisition by TPG Capital, valuing the company at approximately AUD 651 million. The deal, supported by the board and an independent expert, is set to complete by early December 2025.

Nexus Minerals reports robust one-metre assay results from Clement and Godfrey prospects, confirming significant gold mineralisation at Wallbrook. The Crusader-Templar Mine Development and Closure Plan has secured regulatory approval, paving the way for operational progress.

SQX Resources has reported exceptional high-grade gold and silver assays from underground sampling at the Williams Project in Montana, validating historical data and advancing its acquisition of AM6 Pty Ltd.

Lunnon Metals has updated its Lady Herial gold resource to 36,300 ounces at 2.0 g/t, securing Gold Fields’ approval and nearing regulatory green light for mining.

RPMGlobal shareholders are set to vote on Caterpillar’s $5.00 per share acquisition proposal following Federal Court approval to convene a Scheme Meeting. The Independent Expert deems the offer fair and reasonable, with the RPM Board unanimously backing the deal.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.